JP5192485B2 - 向精神性薬物またはｇａｂａアゴニストと有機酸とを含むコンジュゲート、ならびに疼痛および他のｃｎｓ障害を治療するためのそれらの使用 - Google Patents

向精神性薬物またはｇａｂａアゴニストと有機酸とを含むコンジュゲート、ならびに疼痛および他のｃｎｓ障害を治療するためのそれらの使用 Download PDF

Info

Publication number
JP5192485B2
JP5192485B2 JP2009520129A JP2009520129A JP5192485B2 JP 5192485 B2 JP5192485 B2 JP 5192485B2 JP 2009520129 A JP2009520129 A JP 2009520129A JP 2009520129 A JP2009520129 A JP 2009520129A JP 5192485 B2 JP5192485 B2 JP 5192485B2
Authority
JP
Japan
Prior art keywords
gaba
pain
conjugate
nortriptyline
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009520129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543858A (ja
JP2009543858A5 (https=
Inventor
アブラハム ヌデルマン，
アダ レファエリ，
イリット ギル−アド，
アブラハム ウェイズマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of JP2009543858A publication Critical patent/JP2009543858A/ja
Publication of JP2009543858A5 publication Critical patent/JP2009543858A5/ja
Application granted granted Critical
Publication of JP5192485B2 publication Critical patent/JP5192485B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009520129A 2006-07-17 2007-07-17 向精神性薬物またはｇａｂａアゴニストと有機酸とを含むコンジュゲート、ならびに疼痛および他のｃｎｓ障害を治療するためのそれらの使用 Expired - Fee Related JP5192485B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83119506P 2006-07-17 2006-07-17
US83119206P 2006-07-17 2006-07-17
US60/831,192 2006-07-17
US60/831,195 2006-07-17
PCT/IL2007/000903 WO2008010223A2 (en) 2006-07-17 2007-07-17 Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders

Publications (3)

Publication Number Publication Date
JP2009543858A JP2009543858A (ja) 2009-12-10
JP2009543858A5 JP2009543858A5 (https=) 2010-09-02
JP5192485B2 true JP5192485B2 (ja) 2013-05-08

Family

ID=38621178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009520129A Expired - Fee Related JP5192485B2 (ja) 2006-07-17 2007-07-17 向精神性薬物またはｇａｂａアゴニストと有機酸とを含むコンジュゲート、ならびに疼痛および他のｃｎｓ障害を治療するためのそれらの使用

Country Status (11)

Country Link
US (3) US8377990B2 (https=)
EP (1) EP2051735B1 (https=)
JP (1) JP5192485B2 (https=)
KR (1) KR20090048462A (https=)
CN (1) CN101511388B (https=)
AU (1) AU2007274583B2 (https=)
CA (1) CA2659521A1 (https=)
ES (1) ES2393933T3 (https=)
IL (1) IL196538A0 (https=)
MX (1) MX2009000641A (https=)
WO (2) WO2008010223A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
JP5284779B2 (ja) * 2005-06-07 2013-09-11 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法
EP2051735B1 (en) 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
US20090074677A1 (en) * 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
WO2009101616A1 (en) * 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
WO2010027266A1 (en) * 2008-09-05 2010-03-11 Van De Langenberg, Hendrikus Theodorus Ardina Hubertus Means and methods for counteracting neurological disorders
CN105330603A (zh) * 2008-10-08 2016-02-17 凯飞药业公司 Gaba偶联物及其使用方法
US20100272652A1 (en) * 2009-03-26 2010-10-28 Seventh Sense Biosystems, Inc. Determination of tracers within subjects
US8141697B2 (en) * 2009-04-03 2012-03-27 Ackley Machine Corporation Method and apparatus for transporting caplets
JP5675821B2 (ja) * 2009-09-23 2015-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート Ｔｏｌｌ様受容体モジュレーター及びその使用
WO2011070579A1 (en) * 2009-12-09 2011-06-16 Biolinerx Ltd. Methods of improving cognitive functions
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
JP5893135B2 (ja) * 2011-06-28 2016-03-23 ビボゾーン インコーポレイテッド 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途
WO2014022807A2 (en) * 2012-08-03 2014-02-06 Alumend, Llc Compositions and methods of using the compositions for plaque softening
CN113061089A (zh) 2015-09-23 2021-07-02 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
CN110709386B (zh) 2017-03-30 2022-06-07 凯瑞康宁生物工程（武汉）有限公司 双环杂芳基衍生物及其制备与用途
JPWO2018199174A1 (ja) * 2017-04-25 2020-02-27 生化学工業株式会社 第３級アミン化合物又はイミン化合物−ポリマーコンジュゲートとその製造方法
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CN112424158A (zh) * 2018-05-14 2021-02-26 昌郁医药公司 萘普生和普瑞巴林的1-(酰氧基)-烷基氨基甲酸酯药物缀合物的结晶形式
ES2947089T3 (es) 2018-09-30 2023-08-01 Xwpharma Ltd Compuestos como antagonistas del receptor histamínico 3 neuronal y usos de los mismos
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
KR102881504B1 (ko) 2019-12-20 2025-11-06 엑스더블유파마 리미티드 4-발레릴옥시부티르산의 합성 방법
CN115803017A (zh) 2020-06-18 2023-03-14 凯瑞康宁生物工程有限公司 水溶性活性药物成分的药物造粒物
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
KR20230058151A (ko) 2020-10-05 2023-05-02 엑스더블유파마 리미티드 감마-하이드록시부티르산 유도체의 변형된 방출 조성물
EP4588471A3 (en) 2021-03-19 2025-09-24 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
CN114452256A (zh) * 2021-12-31 2022-05-10 浙江大学 脊髓损伤靶向药物、聚合物-疏水化合物胶束及其制备方法
CN115057865B (zh) * 2022-05-10 2023-03-31 国药集团工业有限公司 一种磷酸可待因半水合物的制备方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2944053A (en) 1960-07-05 Uiiilcu
US3058979A (en) 1957-05-13 1962-10-16 Smith Kline French Lab New perfluoroalkylphenothiazine derivatives
US2914528A (en) 1958-04-16 1959-11-24 Smith Kline French Lab Substituted phenothiazinyl trifluoro-methyl sulfones
NL227699A (https=) 1957-09-11 1900-01-01
US2969358A (en) 1958-12-08 1961-01-24 Searle & Co 2-chloro-10-phenothiazinecarbonylpiperazines
GB1460713A (en) 1973-06-08 1977-01-06 Kefalas As 7-fluoro substituted phenothiazines method for preparation thereof and compositions bladed rotor for a gas turbine engine
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US3978216A (en) 1974-06-03 1976-08-31 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US3956493A (en) 1974-10-21 1976-05-11 E. R. Squibb & Sons, Inc. Long acting tranquilizing agent
GB1540842A (en) 1976-08-25 1979-02-14 Kefalas As Phenothiazines
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
JPS6072868A (ja) 1982-10-04 1985-04-24 Fujisawa Pharmaceut Co Ltd 縮合複素環誘導体およびその製造法
US4629691A (en) 1983-08-01 1986-12-16 Syntex (U.S.A.) Inc. Tricyclic antidepressant conjugates with antigens and enzymes
GB8413605D0 (en) 1984-05-29 1984-07-04 Gersan Ets Examining unfinished gemstone
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4818936A (en) 1985-02-15 1989-04-04 The Broken Hill Proprietary Company Limited Method and apparatus for identifying and classifying steels
WO1986004991A1 (en) 1985-02-15 1986-08-28 The Broken Hill Proprietary Company Limited Classification of steel
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
ES8707175A1 (es) 1986-06-13 1987-07-16 Inke Sa Procedimiento para la obtencion de la n-metil-3-(p-trifluorometilfenoxi)-3-fenilpropilamina
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5104858A (en) 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
JPH02128564A (ja) 1988-11-08 1990-05-16 Nec Corp 電話付きパーソナルコンピュータ
JP2801648B2 (ja) 1989-06-14 1998-09-21 日本化薬株式会社 ６―フルオロ―４―クロマノン―２―カルボン酸アミド又はエステルの製造法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU3244793A (en) 1991-12-09 1993-07-19 Gem International Network, Inc. Computer imaging system for gemstones
US5780590A (en) 1993-10-15 1998-07-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
CA2176140A1 (en) 1993-11-24 1995-06-01 Meng Hsin Chen Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5534522A (en) 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
US5952365A (en) 1995-07-13 1999-09-14 Anormed Inc. 2- 2-(Dimethylamino)ethyl!-8,8-dipropyl-2-azaspiro 4.5!decane dimaleate
CA2162532C (en) 1995-11-09 2001-01-30 Dana J. Vanier Gemstone registration system
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
US5966673A (en) 1997-01-10 1999-10-12 Diamond Technologies, Inc. System and method for computerized evaluation of gemstones
US6130221A (en) 1997-03-05 2000-10-10 Nymox Corporation Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6020954A (en) 1997-12-18 2000-02-01 Imagestatistics, Inc. Method and associated apparatus for the standardized grading of gemstones
US5983238A (en) 1997-12-26 1999-11-09 Diamond Id Gemstons identification tracking and recovery system
JP4002006B2 (ja) 1998-06-29 2007-10-31 日本電信電話株式会社 色校正装置、色校正方法、および色校正プログラムを記録した記録媒体
US20010024532A1 (en) 1998-09-21 2001-09-27 Malnekoff Peter J. Automated gemstone evaluation system
US6304853B1 (en) 1998-09-21 2001-10-16 Peter J. Malnekoff Automated gemstone evaluation system
IL134664A0 (en) 1999-10-29 2001-04-30 Diamond And Jewelry 4 U Ltd System for trade in precious gemstones
US6381510B1 (en) 1999-11-19 2002-04-30 Eruggallery.Com Methods and apparatus for facilitating electronic commerce in area rugs
CA2475026A1 (en) * 1999-12-01 2001-06-07 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
GB2379536A (en) 2000-05-23 2003-03-12 David W Hendry Jr System and method for appraising and describing jewelry and other valuable items
US20020021439A1 (en) 2000-08-07 2002-02-21 Derek Priestley Colour matching system
US7251619B2 (en) 2000-09-01 2007-07-31 Garry Ian Holloway Computer implemented method, computer program product, and system for gem evaluation
JP2005097120A (ja) 2000-10-06 2005-04-14 Mochida Pharmaceut Co Ltd ４−ヒドロキシピペリジン誘導体の非潮解性塩
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6569853B1 (en) 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20030065586A1 (en) 2001-07-31 2003-04-03 Shaftel Keith L. Electronic commerce product pricing and selection system and method
US20030115079A1 (en) 2001-08-30 2003-06-19 Rapaport Martin M. Method of and system for ranking optimal values
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
JP4521187B2 (ja) * 2001-09-27 2010-08-11 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド コンジュゲートされた抗精神病薬およびこれらの使用
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
EP1471909A4 (en) 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
EP1500010A4 (en) 2002-01-25 2005-04-27 Menahem Sevdermish METHOD FOR THE DIGITAL COLOR GRADING OF JEWELS AND COMMUNICATION THEREFOR
US8046274B2 (en) 2002-01-25 2011-10-25 Menahem Sevdermish Method for digital color grading of gems and communication thereof
US20040092504A1 (en) 2002-11-12 2004-05-13 Anuthep Benja-Athon Definitive medications for treating fibromyalgia
EP1675555A4 (en) 2003-09-30 2011-03-09 Shire Llc PHARMACEUTICAL COMPOSITIONS FOR PREVENTING EXCESSIVE DOSE OR ABUSE
AR054181A1 (es) * 2004-08-26 2007-06-06 Nicholas Piramal India Ltd Prodrogas que contienen enlaces bio-divisibles. composiiciones farmaceuticas
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US7151084B2 (en) 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
US7074775B2 (en) 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
TW200715156A (en) 2004-11-24 2007-04-16 Interdigital Tech Corp Intelligent information dissemination using a dynamic profile
JP5284779B2 (ja) 2005-06-07 2013-09-11 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法
WO2007050318A2 (en) 2005-10-24 2007-05-03 Duke University Lipidomics approaches for central nervous system disorders
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
ES2573733T3 (es) 2006-05-22 2016-06-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento farmacológico del deterioro cognitivo
EP2051735B1 (en) 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
WO2009101616A1 (en) 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
US8377929B2 (en) 2010-02-24 2013-02-19 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same

Also Published As

Publication number Publication date
US20130059910A1 (en) 2013-03-07
EP2051735B1 (en) 2012-08-29
US8222296B2 (en) 2012-07-17
WO2008010223A2 (en) 2008-01-24
WO2008010223A3 (en) 2008-03-20
MX2009000641A (es) 2009-02-12
JP2009543858A (ja) 2009-12-10
WO2008010222A2 (en) 2008-01-24
WO2008010222A3 (en) 2008-04-10
ES2393933T3 (es) 2013-01-02
US8377990B2 (en) 2013-02-19
KR20090048462A (ko) 2009-05-13
CN101511388A (zh) 2009-08-19
US20090304584A1 (en) 2009-12-10
AU2007274583B2 (en) 2012-11-01
CA2659521A1 (en) 2008-01-24
CN101511388B (zh) 2012-10-24
AU2007274583A1 (en) 2008-01-24
US20100144869A1 (en) 2010-06-10
IL196538A0 (en) 2009-11-18
EP2051735A2 (en) 2009-04-29

Similar Documents

Publication Publication Date Title
JP5192485B2 (ja) 向精神性薬物またはｇａｂａアゴニストと有機酸とを含むコンジュゲート、ならびに疼痛および他のｃｎｓ障害を治療するためのそれらの使用
CN103025326B (zh) 治疗不安腿综合征的方法
US11040022B2 (en) Compositions and methods for pain relief
JP2019527226A (ja) ヒストンアセチルトランスフェラーゼ活性化剤及び組成物並びにそれらの使用
JP2014015472A (ja) コンジュゲートされた抗精神病薬およびこれらの使用
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
RU2002111355A (ru) Производные 5бета-сапогенина и псевдосапогенина и их применение при лечении деменции
JP6617702B2 (ja) Ｆｔｙ７２０のアザサイクリック拘束アナログ
JP2025023120A (ja) ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
CN109758455A (zh) 胺类化合物的光学异构体治疗疼痛的医药用途
JP2010513534A (ja) Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
JPWO2007020935A1 (ja) Ｐ２ｙ１２受容体および／またはｐ２ｙ１４受容体ブロッカーを含有してなる疼痛治療剤
JP6924184B2 (ja) 疼痛の治療のための医薬組成物
WO2013042005A1 (en) N- substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders
JP2020019722A (ja) 神経障害性疼痛の医薬組成物
AR127243A1 (es) Compuestos, composiciones farmacéuticas y métodos para el tratamiento, prevención o manejo de trastornos hiperproliferativos
JP2019509321A (ja) 疼痛を処置するための組み合わせ
RU2776842C2 (ru) Применение агониста kor в комбинации с агонистом mor для получения лекарственного средства для лечения боли
JP2005060311A (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
CN101355947B (zh) 用于治疗的噻唑并嘧啶类
WO2007020403A1 (en) Azapeptides for treating hyperalgesic pain conditions
HK1178796B (en) Methods of treating restless legs syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121004

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130131

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160208

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees